$0.003 0.0 21.7%
Last Trade - 25/02/21
| Market Cap | £930k |
| Enterprise Value | £2.33m |
| Revenue | £77.6k |
| Position in Universe | th / 6713 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Sep | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.19 | 0.10 | 0.11 | 0.10 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Regen Biopharma, Inc. is a biotechnology company. The Company is focused on identifying regenerative medicine applications in the stem cell/immunotherapy space and advancing these technologies through pre-clinical and Phase I/II clinical trials. The Company is developing products treating blood disorders using small molecules and gene silencing, treating cancer with immunotherapy, modulating molecular processes in cancer stem cell through its molecular targeting approaches, and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients. The Company's products include HemaXellarate I, HemaXellerate II, dCellVax, NR2F6 and Tcellvax. The Company is also identifying small molecules through a screening program that inhibits NR2F6 leading to immune cell activation for oncology applications. The Company is also developing drugs that modulate telomere maintenance.
| Last Annual | September 30th, 2018 |
| Last Interim | June 30th, 2019 |
| Incorporated | April 24, 2012 |
| Public Since | September 3, 2014 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Pink Sheets on Nasdaq |
| Shares in Issue | 571,484,406 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 4700 Spring St Ste 304, LA MESA, 91942-0274, United States |
| Web | https://www.regenbiopharmainc.com/ |
| Phone | +1 619 7021404 |
| Contact | () |
| Auditors | AMC Auditing, LLC |
As of 25/02/21, shares in Regen BioPharma Inc are trading at $0.003, giving the company a market capitalisation of £930k. This share price information is delayed by 15 minutes.
Shares in Regen BioPharma Inc are currently trading at $0.003 and the price has moved by 1.43k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Regen BioPharma Inc price has moved by 1.12k% over the past year.
There are no analysts currently covering Regen BioPharma Inc.
Regen BioPharma Inc is scheduled to issue upcoming financial results on the following dates:
Regen BioPharma Inc does not currently pay a dividend.
Regen BioPharma Inc does not currently pay a dividend.
Regen BioPharma Inc does not currently pay a dividend.
To buy shares in Regen BioPharma Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Regen BioPharma Inc are currently trading at $0.003, giving the company a market capitalisation of £930k.
Here are the trading details for Regen BioPharma Inc:
We were not able to load our ranking data for Regen BioPharma Inc
We were not able to load any forecast data for Regen BioPharma Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Regen BioPharma Inc. Over the past six months, the relative strength of its shares against the market has been 0.294k%. At the current price of $0.003, shares in Regen BioPharma Inc are trading at 0.279k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Regen BioPharma Inc.
Regen BioPharma Inc's management team is headed by:
Here are the top five shareholders of Regen BioPharma Inc based on the size of their shareholding:
